Trispecific CAR T Cell Therapy Shows Promise in Trials
A small study suggests this new treatment approach may help some adults with relapsed B-cell malignancies.
Updated on Oct. 21, 2026 in Cancer
In a phase 1 trial published in 2026, researchers at The Ohio State University James Comprehensive Cancer Center tested trispecific CAR T cells in patients with relapsed or refractory B-cell malignancies. The early-stage results showed promise, though larger studies are required to confirm these findings for patients.
Why it matters
This study explores a potential new cellular therapy approach that could offer an alternative for patients with B-cell malignancies who have exhausted standard treatment options. The trial highlights a rapid manufacturing process that may improve access to these custom treatments in the future.
In a phase 1 study of 16 patients, researchers achieved an 83% complete response rate for B-cell non-Hodgkin lymphoma. While the treatment showed a 50% overall response rate for the full cohort, larger validation trials are necessary to confirm these preliminary results.
The players
The Ohio State University James Comprehensive Cancer Center
A research institution in Columbus that conducted the clinical trial.
The details
The treatment involves re-engineering immune cells to target cancer through a trispecific mechanism. Patients first receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine to clear the way for the infusion of these modified cells. The study successfully demonstrated that the manufacturing of these cells can be completed in a median time of 7 days, with no dose-limiting toxicities identified across three tested levels.
Timeline
2026: Results from the phase 1 trial are published in Blood Cancer Discovery.
1 year after infusion: Four out of five complete responders remained in remission.
Health Landscape
This study is part of an ongoing effort to evolve CAR T-cell treatments beyond standard single-target designs. It contributes to the broader oncology research landscape by testing whether trispecific cells can improve outcomes for patients with refractory malignancies.
Patients with relapsed B-cell malignancies should consult their oncologist about the availability of clinical trials investigating novel CAR T-cell therapies. Because this trial was preliminary, it is essential to discuss the potential risks, including the 25% incidence of cytokine release syndrome, with a specialist.
The takeaway
This phase 1 trial shows that trispecific CAR T cells can produce complete responses in some patients with B-cell non-Hodgkin lymphoma. If you are exploring advanced treatment options, ask your physician about emerging cellular therapy trials and the eligibility criteria for participating in such studies.
Further reading
Learn more about the latest innovations in Cancer care and research.
Source note: This article includes information reported by Cancernetwork.
